As described in a previous section, more work is required to determine whether different types of PPAR drug targets may have any potential benefit in alleviating inflammation in sepsis, thereby potentially preventing and/or improving certain deleterious consequences associated with the condition. This evidence concerns the gene PPARA and Sepsis.